You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm is investing in studies that use its multiplex microarray platform to monitor lupus disease activity and traumatic brain injury response.
A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.
The meta-analysis drew on studies conducted in both European and Chinese populations, and hinted at why lupus may be more common among East Asians.
Firalis is developing an assay based on HTG's EdgeSeq platform to identify rheumatoid arthritis patients likely to respond to anti-TNF-alpha therapies.
An international research team studied how genetic factors control immune cell response to pathogens in healthy individuals.
Certain bacterial species appear more common in gut microbiomes of individuals with MS, coinciding with inflammation-related gene expression in host blood.
The collaboration will use Transplant Genomics' TruGraf test for post-kidney transplant monitoring to try to personalize immunosuppression therapies.
The company now offers three CE-marked autoantibody assays — for BICD2, Scl70, and CENP-B — that can be used for clinical management of the condition.
A team of scientists and entrepreneurs is trying to build a company around a dataset from a large multi-omics clinical study funded by Genome Canada.
The funding will support development of tests that detect cell-free DNA methylation patterns indicative of disease in specific tissues of the body.
The company said it has enlisted 23 academic and medical institutions to supply patient samples that will support the validation and launch of its tests.
Researchers identified a common variant in a long non-coding RNA that may contribute to inflammation seen in patients diagnosed with celiac disease.
A mutation uncovered in a Belgian family through genetic analysis disrupts pyrin protein regulation to lead to an autoinflammatory disease.
The firm has not disclosed the specific disease the test will address but has determined this space represents the best opportunity for its array technology.
The new study in NEJM describes six families that share a disorder caused by mutations in IKAROS, a protein that plays a role in immune cell development.
The partners will collaborate on point-of-care tests for validating the identity and activity of biologics and biosimilars.
The approach can increase CpG coverage about 18-fold by inferring from existing data to predict methylation of sites outside those covered on the arrays themselves.
Under the terms of the deal, IQuity's autoimmune disease diagnostics will be made available through Diatherix's CLIA-certified clinical laboratory.
The Dutch firm plans to develop a complete, CE-marked pipeline for NGS-base HLA typing, from DNA amplification to software analysis.
After scrapping initial plans to develop a diagnostic instrument, the company has been working for several years to advance its single-cell droplet platform for targeted drug development.
New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.
According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.
The US National Institutes of Health has a new initiative to address structural racism in biomedical research.
In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.